In the last two decades, the use of cannabis for medical purposes has become legal in many countries and its use is steadily increasing. One of the most frequently cited reasons for prescribing medicinal cannabis (MC) is management of chronic pain, and in recent years MC has also been used as a treatment of psychiatric conditions such as post-traumatic stress disorder (PTSD). However, little is known about patients’ experiences of the long-term physiological and psycho-social effects of MC use. In this study, we focused on Israeli MC patients’ experiences in order to gain further understanding of the long-term effects of MC and explore narratives evolving from chronic pain and PTSD patients regarding their MC treatment. In-depth semi-structured interviews were conducted among participants prescribed MC for chronic pain or PTSD (n = 25), predominantly men. Thematic analysis was applied to characterize content, semantics, experience, and narratives of participants regarding their MC use. Two main themes were developed: (1) Coping mechanisms related to the adverse effects of MC use, which included Concealment, Justification, Protective behavioral strategies, and Rejection of “pothead” identity; and (2) Utilization of MC’s positive effects, which included Forget/Disconnect, Helplessness/Despair, and Camaraderie against authorities. MC patients described coping strategies with experienced negative effects of MC use and utilization of MC treatment for various psychiatric, psychological, and social needs.
AdlerL.ZacayG.SchonmannY.AzuriJ.YehoshuaI.VinkerS.ShaniM.HeymannA. D.HoffmanR. (2022). Primary care physicians’ attitudes and knowledge regarding medical cannabis and willingness to prescribe it: The Israeli experience. Family Practice, 39(1), 59–64. https://doi.org/10.1093/fampra/cmab108
2.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (DSM-4). American Psychiatric Publishing. https://doi.org/10.1176/ajp.152.8.1228
Ashwal-MalkaA.Tal-KishnerK.FeingoldD. (2022). Moral injury and cannabis use disorder among Israeli combat veterans: The role of depression and perceived social support. Addictive Behaviors, 124, Article 107114. https://doi.org/10.1016/j.addbeh.2021.107114
5.
BallantyneA. (2015). Adjusting the focus: A public health ethics approach to data research. Bioethics, 29(7), 413–423. https://doi.org/10.1111/bioe.12133
6.
BergenN.LabonteR. (2020). “Everything is perfect, and we have no problems”: Detecting and limiting social desirability bias in qualitative research. Qualitative Health Research, 30(5), 783–792. https://doi.org/10.1177/1049732319889354
7.
BenniciA.MannucciC.CalapaiF.CardiaL.AmmendoliaI.GangemiS.CalapaiG.Griscti SolerD. (2021). Safety of medical cannabis in neuropathic chronic pain management. Molecules, 26(20), Article 6257. https://doi.org/10.3390/molecules26206257
8.
BilbaoA.SpanagelR. (2022). Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine, 20(1), Article 259. https://doi.org/10.1186/s12916-022-02459-1
9.
BlevinsC. E.AbrantesA. M.AndersonB. J.CavinessC. M.HermanD. S.SteinM. D. (2018). Identity as a cannabis user is related to problematic patterns of consumption among emerging adults. Addictive Behaviors, 79, 138–143. https://doi.org/10.1016/j.addbeh.2017.12.021
10.
BoehnkeK. F.GangopadhyayS.ClauwD. J.HaffajeeR. L. (2019). Qualifying conditions of medical cannabis license holders in the United States. Health Affairs, 38(2), 295–302. https://doi.org/10.1377/hlthaff.2018.05266
11.
BorodovskyJ. T.SofisM. J.GruczaR. A.BudneyA. J. (2021). The importance of psychology for shaping legal cannabis regulation. Experimental and Clinical Psychopharmacology, 29(1), 99–115. https://doi.org/10.1037/pha0000362
12.
BraunV.ClarkeV. (2019). Reflecting on reflexive thematic analysis. Qualitative Research in Sport, Exercise and Health, 11(4), 589–597. https://doi.org/10.1080/2159676X.2019.1628806
13.
BraunV.ClarkeV. (2021). Can I use TA? Should I use TA? Should I not use TA? Comparing reflexive thematic analysis and other pattern‐based qualitative analytic approaches. Counselling and Psychotherapy Research, 21(1), 37–47. https://doi.org/10.1002/capr.12360
14.
BraunV.ClarkeV. (2023). Is thematic analysis used well in health psychology? A critical review of published research, with recommendations for quality practice and reporting. Health Psychology Review, 17(4), 695–718. https://doi.org/10.1080/17437199.2022.2161594
15.
CahillS. P.LunnS. E.DiazP.PageJ. E. (2021). Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Frontiers in Public Health, 9, Article 626853. https://doi.org/10.3389/fpubh.2021.626853
16.
CampbellG.StockingsE.NielsenS. (2019). Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 135–144. https://doi.org/10.1007/s00406-018-0960-9
17.
ChungT.SteinbergM. L.BridgemanM. B. (2023). Recommendation for Cannabis Use Disorder Diagnosis in a Context of Cannabis for Therapeutic Purposes. JAMA Psychiatry, 80(5), 409–410. https://doi.org/10.1001/jamapsychiatry.2023.0053
18.
ConnorJ. P.StjepanovićD.Le FollB.HochE.BudneyA. J.HallW. D. (2021). Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 7(1), 16–24. https://doi.org/10.1038/s41572-021-00247-4
19.
CrokerJ. A.IIIBobittJ. L.AroraK.KaskieB. (2021). Assessing health-related outcomes of medical cannabis use among older persons: Findings from Colorado and Illinois. Clinical Gerontologist, 44(1), 66–79. https://doi.org/10.1080/07317115.2020.1797971
20.
DahlkeS.ButlerJ. I.HunterK. F.ToubianaM.KalogirouM. R.ShresthaS.DevkotaR.LawJ.ScheuermanM. (2024). The effects of stigma: Older persons and medicinal cannabis. Qualitative Health Research, 34(8–9), 717–731. https://doi.org/10.1177/10497323241227419
21.
DawsonD.StjepanovicD.LorenzettiV.CheungC.HallW.LeungJ. (2024). The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis. Drug and Alcohol Dependence, 257(1–2), Article 111263. https://doi.org/10.1016/j.drugalcdep.2023.111263
22.
DellazizzoL.PotvinS.GiguèreS.DumaisA. (2022). Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: A systematic meta-review of meta-analyses. Addiction, 117(7), Article 1857. https://doi.org/10.1111/add.15960
23.
FeingoldD.GliksbergO. (2023). Defining problematic use of medicinal cannabis: Theoretical and empirical considerations. In PreedyV. R.PatelV. B.MartinC. R. (Eds.), Medicinal usage of cannabis and cannabinoids (pp. 105–116). Academic Press. https://doi.org/10.1016/B978-0-323-90036-2.00006-5
24.
FeingoldD.GliksbergO.BrillS.AmitB. H.Lev-RanS.KushnirT.SznitmanS. R. (2024). Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire. Addictive Behaviors, 158(1–2), Article 108122. https://doi.org/10.1016/j.addbeh.2024.108122
FeingoldD.LivneO.RehmJ.Lev-RanS. (2020). Probability and correlates of transition from cannabis use to DSM‐5 cannabis use disorder: Results from a large‐scale nationally representative study. Drug and Alcohol Review, 39(2), 142–151. https://doi.org/10.1111/dar.13031
27.
FeingoldD.ZerachG.Levi-BelzY. (2019). The association between moral injury and substance use among Israeli combat veterans: The mediating role of distress and perceived social support. International Journal of Mental Health and Addiction, 17(2), 217–233. https://doi.org/10.1007/s11469-018-0012-8
28.
FlickU. (2017). Mantras and myths: The disenchantment of mixed-methods research and revisiting triangulation as a perspective. Qualitative Inquiry, 23(1), 46–57. https://doi.org/10.1177/1077800416655827
29.
FontanaA.FreyJ. H. (2005). The interview: From neutral stance to political involvement. In DenzinN. K.LincolnY. S. (Eds.), The Sage handbook of qualitative research (pp. 695–727). Sage Publications.
30.
GliksbergO.KushnirT.SznitmanS. R.Lev-RanS.BrillS.AmitB. H.FeingoldD. (2023). Negative experiences of patients using medicinal cannabis: A systematic review of qualitative studies. Journal of Clinical Nursing, 32(17–18), 5607–5618. https://doi.org/10.1111/jocn.16653
31.
HaslerW. L.AlshaarawyO.VenkatesanT. (2025). Cannabis use patterns and association with hyperemesis: A comprehensive review. Neuro-Gastroenterology and Motility, 37(3), Article e14895. https://doi.org/10.1111/nmo.14895
32.
HawnS. E.CusackS. E.AmstadterA. B. (2020). A systematic review of the self‐medication hypothesis in the context of posttraumatic stress disorder and comorbid problematic alcohol use. Journal of Traumatic Stress, 33(5), 699–708. https://doi.org/10.1002/jts.22521
33.
HemsingN.GreavesL. (2020). Gender norms, roles and relations and cannabis-use patterns: A scoping review. International Journal of Environmental Research and Public Health, 17(3), Article 947. https://doi.org/10.3390/ijerph17030947
34.
HendersonL. A.KotsirilosV.CairnsE. A.RamachandranA.PeckC. C.McGregorI. S. (2021). Medicinal cannabis in the treatment of chronic pain. Australian Journal of General Practice, 50(10), 724–732. https://doi.org/10.31128/AJGP-04-21-5939
35.
HerchenroederL.MezquitaL.BravoA. J.PilattiA.PrinceM. A.Cross-Cultural Addictions Study Team. (2022). A cross-national examination of cannabis protective behavioral strategies’ role in the relationship between Big Five personality traits and cannabis outcomes. The American Journal of Drug and Alcohol Abuse, 48(1), 27–37. https://doi.org/10.1080/00952990.2021.1919689
36.
HillK. P.GoldM. S.NemeroffC. B.McDonaldW.GrzendaA.WidgeA. S.RodriguezC.KraguljacN. V.KrystalJ. H.CarpenterL. L. (2022). Risks and benefits of cannabis and cannabinoids in psychiatry. American Journal of Psychiatry, 179(2), 98–109. https://doi.org/10.1176/appi.ajp.2021.21030320
37.
HirschiT. (1969). Key idea: Hirschi’s social bond/social control theory. Key Ideas in Criminology and Criminal Justice, 1969, 55–69. https://doi.org/10.4324/9781315081649
38.
HochE.NiemannD.von KellerR.SchneiderM.FriemelC. M.PreussU. W.HasanA.PogarellO. (2019). How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 87–105. https://doi.org/10.1007/s00406-019-00984-4
39.
HulaihelA.GliksbergO.FeingoldD.BrillS.AmitB. H.Lev-RanS.SznitmanS. R. (2023). Medical cannabis and stigma: A qualitative study with patients living with chronic pain. Journal of Clinical Nursing, 32(7–8), 1103–1114. https://doi.org/10.1111/jocn.16340
40.
Israeli Ministry of Health (2024). Updated data of medical cannabis licenses.
41.
IsralowitzR.ReznikA.ZolotovY.Grinstein-CohenO.WachtO.PrugininI.YehudaiM.EdelsteinO. (2021). Toward medical cannabis education in Israel. Complementary Therapies in Medicine, 58(2), Article 102709. https://doi.org/10.1016/j.ctim.2021.102709
42.
KimG. J. (2022). Examining the predictors of medical marijuana legalization in the United States using an empirically based taxonomy approach. Policy Studies, 43(2), 183–202. https://doi.org/10.1080/01442872.2019.1656805
43.
KosibaJ. D.MaistoS. A.DitreJ. W. (2019). Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Social Science & Medicine, 233, 181–192. https://doi.org/10.1016/j.socscimed.2019.06.005
44.
LaFranceE. M.GlodoskyN. C.Bonn-MillerM.CuttlerC. (2020). Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. Journal of Affective Disorders, 274, 298–304. https://doi.org/10.1016/j.jad.2020.05.132
45.
Lavie-AjayiM.ZivA.PinsonH.RamH.AvieliN.ZurE.TzurE.NimrodG. (2022). Recreational cannabis use and identity formation: A collective memory work study. World Leisure Journal, 64(4), 325–341. https://doi.org/10.1080/16078055.2022.2043428
46.
LawnW.Fernandez-VinsonN.MokryszC.HoggG.LeesR.TrinciK.PetrilliK.BorissovaA.OforiS.WatersS.MichórP.WallM. B.FreemanT. P.CurranH. V. (2022). The CannTeen study: Verbal episodic memory, spatial working memory, and response inhibition in adolescent and adult cannabis users and age-matched controls. Psychopharmacology, 239(5), 1629–1641. https://doi.org/10.1007/s00213-022-06143-3
47.
LeungJ.ChanG.StjepanovićD.ChungJ. Y. C.HallW.HammondD. (2022). Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology, 239(5), 1509–1519. https://doi.org/10.1007/s00213-021-06047-8
48.
LinL. A.IlgenM. A.JannauschM.BohnertK. M. (2016). Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addictive Behaviors, 61, 99–103. https://doi.org/10.1016/j.addbeh.2016.05.015
49.
LisboaS. F.Vila-VerdeC.RosaJ.UlianaD. L.SternC. A. J.BertoglioL. J.ResstelL. B.GuimaraesF. S. (2019). Tempering aversive/traumatic memories with cannabinoids: A review of evidence from animal and human studies. Psychopharmacology, 236(1), 201–226. https://doi.org/10.1007/s00213-018-5127-x
50.
LucasP.BaronE. P.JikomesN. (2019). Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduction Journal, 16(1), 1–11. https://doi.org/10.1186/s12954-019-0333-3
51.
MahalikJ. R.LombardiC. M.SimsJ.ColeyR. L.LynchA. D. (2015). Gender, male-typicality, and social norms predicting adolescent alcohol intoxication and marijuana use. Social Science & Medicine, 143, 71–80. https://doi.org/10.1016/j.socscimed.2015.08.013
52.
MayoL. M.RabinakC. A.HillM. N.HeiligM. (2022). Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: A promising case of preclinical-clinical translation?Biological Psychiatry, 91(3), 262–272. https://doi.org/10.1016/j.biopsych.2021.07.019
53.
MechoulamR. (2016). Cannabis–the Israeli perspective. Journal of Basic and Clinical Physiology and Pharmacology, 27(3), 181–187. https://doi.org/10.1515/jbcpp-2015-0091
54.
MetrikJ.StevensA. K.GunnR. L.BorsariB.JacksonK. M. (2022). Cannabis use and posttraumatic stress disorder: Prospective evidence from a longitudinal study of veterans. Psychological Medicine, 52(3), 446–456. https://doi.org/10.1017/S003329172000197X
NacaschN.AvniC.TorenP. (2023). Medical cannabis for treatment-resistant combat PTSD. Frontiers in Psychiatry, 13, Article 1014630. https://doi.org/10.3389/fpsyt.2022.1014630
57.
PearsonM. R. (2013). Use of alcohol protective behavioral strategies among college students: A critical review. Clinical Psychology Review, 33(8), 1025–1040. https://doi.org/10.1016/j.cpr.2013.08.006
58.
PennayA.MooreD. (2010). Exploring the micro-politics of normalisation: Narratives of pleasure, self-control and desire in a sample of young Australian ‘party drug’ users. Addiction Research and Theory, 18(5), 557–571. https://doi.org/10.3109/16066350903308415
59.
PetzkeF.TölleT.FitzcharlesM. A.HäuserW. (2022). Cannabis-based medicines and medical cannabis for chronic neuropathic pain. CNS Drugs, 36(1), 31–44. https://doi.org/10.1007/s40263-021-00879-w
60.
PintoJ. V.MedeirosL. S.da RosaG. S.de OliveiraC. E. S.de Souza CrippaJ. A.PassosI. C.Kauer-Sant’AnnaM. (2019). The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. Neuroscience & Biobehavioral Reviews, 101, 78–84. https://doi.org/10.1016/j.neubiorev.2019.03.004
61.
PrattM.StevensA.ThukuM.ButlerC.SkidmoreB.WielandL. S.HuttonB. (2019). Benefits and harms of medical cannabis: A scoping review of systematic reviews. Systematic Reviews, 8, 1–35. https://doi.org/10.1186/s13643-019-1123-3
RichardsD. K.SchwebelF. J.PearsonM. R.Study TeamP. S. (2022). A test of interaction effects between cannabis protective behavioral strategies and antecedents of cannabis-related consequences. Journal of Psychoactive Drugs, 54(1), 61–69. https://doi.org/10.1080/02791072.2021.1909188
64.
RobinsonT.AliM. U.EasterbrookB.HallW.Jutras-AswadD.FischerB. (2022). Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: A systematic review and meta-analysis. Psychological Medicine, 53(9), 1–11. https://doi.org/10.1017/S0033291722003580
65.
Roy‐ByrneP.MaynardC.BumgardnerK.KrupskiA.DunnC.WestI. I.RiesR. (2015). Are medical marijuana users different from recreational users? The view from primary care. The American Journal on Addictions, 24(7), 599–606. https://doi.org/10.1111/ajad.12270
66.
SandelowskiM. (2001). Real qualitative researchers do not count: The use of numbers in qualitative research. Research in Nursing & Health, 24(3), 230–240. https://doi.org/10.1002/nur.1025
SolimanN.HaroutounianS.HohmannA. G.KraneE.LiaoJ.MacleodM.SegelckeD.SenaC.ThomasJ.VollertJ.WeverK.AlaverdyanH.BarakatA.BarthlowT.BozerA. L. H.DavidsonA.Diaz-delCastilloM.DolgorukovaA.FerdousiM. I.RiceA. S. C. (2021). Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain, 162(Suppl 1), S26–S44. https://doi.org/10.1097/j.pain.0000000000002269
69.
SznitmanS. R. (2017). The Cannabis Abuse Screening Test (CAST) revisited: Examining measurement invariance by age. International Journal of Methods in Psychiatric Research, 26(4), Article e1529. https://doi.org/10.1002/mpr.1529
70.
SznitmanS. R. (2020). Trends in medical cannabis licensure, Israel, 2013–2018. Drug and Alcohol Review, 39(6), 763–767. https://doi.org/10.1111/dar.13116
71.
SznitmanS. R.RoomR. (2018). Rethinking indicators of problematic cannabis use in the era of medical cannabis legalization. Addictive Behaviors, 77, 100–101. https://doi.org/10.1016/j.addbeh.2017.09.026
72.
SznitmanS. R.TaubmanD. S. (2016). Drug use normalization: A systematic and critical mixed-methods review. Journal of Studies on Alcohol and Drugs, 77(5), 700–709. https://doi.org/10.15288/jsad.2016.77.700
73.
TetraultJ. M.ButnerJ. L. (2015). Non-medical prescription opioid use and prescription opioid use disorder: A review. The Yale Journal of Biology and Medicine, 88(3), 227–233.
74.
TurnaJ.BalodisI.MunnC.Van AmeringenM.BusseJ.MacKillopJ. (2020). Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Comprehensive Psychiatry, 102, Article 152188. https://doi.org/10.1016/j.comppsych.2020.152188
75.
TurnerD. W.IIIHagstrom-SchmidtN. (2022). Qualitative interview design. Howdy or hello? Technical and professional communication. The Qualitative Report, 15(1), 754–760.
76.
United Nations Office on Drugs. (2021). World drug report 2021. United Nations Publications.
77.
WallisD.CoatsworthJ. D.MennisJ.RiggsN. R.ZaharakisN.RussellM. A.BrownA. R.RayburnS.RadfordA.HaleC.MasonM. J. (2022). Predicting self-medication with Cannabis in young adults with hazardous Cannabis use. International Journal of Environmental Research and Public Health, 19(3), Article 1850. https://doi.org/10.3390/ijerph19031850
78.
WangL.HongP. J.MayC.RehmanY.OparinY.HongC. J.HongB. Y.AminiLariM.GalloL.KaushalA.CraigieS.CoubanR. J.KumE.ShanthannaH.PriceI.UpadhyeS.WareM. A.CampbellF.BuchbinderR.BusseJ. W. (2021). Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: A systematic review and meta-analysis of randomised clinical trials. BMJ, 374, Article n1034. https://doi.org/10.1136/bmj.n1034
79.
WuG.LiuJ.BoatengF. D.CuiS.ShuaiH. (2021). Do social bonds matter? Social control theory and its relationship to desistance from substance abuse in China. Journal of Drug Issues, 51(1), 50–67. https://doi.org/10.1177/0022042621990190
